Unstable active delivery in oral environments leads to poor bioavailability and short contact times. Engineering the specific interaction between arginine and gelling polymers ensures sustained therapeutic release and structural stability.
Standard oral formulations often fail to maintain effective concentrations of arginine on dental surfaces during use. Improving the residence time and stability of the active matrix ensures therapeutic efficacy against dental hypersensitivity and caries.